These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28166460)

  • 1. An evaluation of increasing sample size based on conditional power.
    Gaffney M; Ware JH
    J Biopharm Stat; 2017; 27(5):797-808. PubMed ID: 28166460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive sample size modification in clinical trials: start small then ask for more?
    Jennison C; Turnbull BW
    Stat Med; 2015 Dec; 34(29):3793-810. PubMed ID: 26172385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size re-estimation in Phase 2 dose-finding: Conditional power versus Bayesian predictive power.
    Liu Q; Hu G; Ye B; Wang S; Wu Y
    Pharm Stat; 2023 Mar; 22(2):349-364. PubMed ID: 36418025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
    Wu PS; Lin M; Chow SC
    J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the "promising zone" design.
    Edwards JM; Walters SJ; Kunz C; Julious SA
    Trials; 2020 Dec; 21(1):1000. PubMed ID: 33276810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
    Mauer M; Collette L; Bogaerts J;
    Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment.
    Wang G; Kennedy RE; Cutter GR; Schneider LS
    Alzheimers Dement (N Y); 2015 Jun; 1(1):63-71. PubMed ID: 29854926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reassessment of trial perspectives from interim data--a critical view.
    Bauer P; Koenig F
    Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study.
    McClure LA; Szychowski JM; Benavente O; Hart RG; Coffey CS
    Clin Trials; 2016 Oct; 13(5):537-44. PubMed ID: 27094488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Stat Methods Med Res; 2019 Jun; 28(6):1852-1878. PubMed ID: 29869564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size re-estimation for pivotal clinical trials.
    Liu Y; Xu H
    Contemp Clin Trials; 2021 Mar; 102():106215. PubMed ID: 33217555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal flexible sample size design with robust power.
    Zhang L; Cui L; Yang B
    Stat Med; 2016 Aug; 35(19):3385-96. PubMed ID: 26999385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal adaptive promising zone designs.
    Mehta C; Bhingare A; Liu L; Senchaudhuri P
    Stat Med; 2022 May; 41(11):1950-1970. PubMed ID: 35165917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four simple ways to increase power without increasing the sample size.
    Lazic SE
    Lab Anim; 2018 Dec; 52(6):621-629. PubMed ID: 29629616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive blinded sample size adjustment for comparing two normal means--a mostly Bayesian approach.
    Hartley AM
    Pharm Stat; 2012; 11(3):230-40. PubMed ID: 22422722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches.
    Shih WJ; Li G; Wang Y
    Contemp Clin Trials; 2016 Mar; 47():40-8. PubMed ID: 26674739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.